Financial Times  Nov 13  Comment 
Sanofi may sell Merial — and trigger a flurry of deals
FierceBiotech  Nov 12  Comment 
FiercePharma's Carly Helfand and FierceBiotech's Damian Garde discuss Sanofi's uninspiring forecast, Amgen's return to high-dollar dealmaking and a lawsuit that accuses a drug company of deliberately being bad at making drugs.
Benzinga  Nov 12  Comment 
Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical company, today announced positive interim results from a Phase IV Study assessing the effects of a nighttime administration of Silenor 6 mg, zolpidem 10 mg, and placebo...
FierceBiotech  Nov 12  Comment 
When it comes to publishing a full set of trial data on new drugs, the biopharma industry overall has a poor record on transparency, according to a new report from a bioethics watchdog group. And some companies--like Sanofi and Gilead--fall well...
FierceBiotech  Nov 10  Comment 
Back in 2011, when Sanofi acquired Genzyme for about $20 billion, it promised the company's shareholders up to $3.8 billion more tied to the then-in-development multiple sclerosis treatment Lemtrada. Things went awry in 2013 when the FDA rejected...
Reuters  Nov 9  Comment 
A new lawsuit accuses Sanofi SA of stalling development of its multiple sclerosis drug Lemtrada to avoid paying out at least $708 million to rights holders under its 2011 agreement...
FierceBiotech  Nov 9  Comment 
Olivier Brandicourt got his first shot at Sanofi's lead role in an annual investor day, and the reviews are not good. Brandicourt had a tough message to sell. The company's diabetes franchise is getting hammered, with the all-important Lantus...


Very nice site!

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki